Mesoblast Limited (NASDAQ:MESO) currently has an Average Broker Rating of 1.67. This number is based on the 6 sell-side firms polled by Zacks. The ABR rank within the industry stands at 10.
Analysts on a consensus basis are expecting that the stock will reach $12.63 within the year. The ABR is provided by Zacks which simplfies analyst ratings into an integer based number. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating.
Research analysts study publicly traded companies and make recommendations on the securities of those companies. Most specialize in a particular industry or sector of the economy. They exert considerable influence in today’s marketplace. Analysts’ recommendations or reports can influence the price of a company’s stock—especially when the recommendations are widely disseminated through television appearances or through other electronic and print media. The mere mention of a company by a popular analyst can temporarily cause its stock to rise or fall—even when nothing about the company’s prospects or fundamentals has recently changed.
Analysts often use a variety of terms—buy, strong buy, near-term or long-term accumulate, near-term or long-term over-perform or under-perform, neutral, hold—to describe their recommendations. But the meanings of these terms can differ from firm to firm. Rather than make assumptions, investors should carefully read the definitions of all ratings used in each research report. They should also consider the firm’s disclosures regarding what percentage of all ratings fall into either “buy,” “hold/neutral,” and “sell” categories.
When putting hard earned money at risk, investors will want to look at all the angles in order to make sure that no stone is left unturned when building the stock portfolio. With so many different stocks available to trade, investors may need to figure out a way to make the selection process manageable. Some investors may choose to start with industry research first and eventually filter down to individual stock picks. Others may want to start at the individual stock level and go from there. Whatever the approach the investor chooses, putting in the time and effort might greatly help the long-term performance of the stock portfolio.
Research analysts are predicting that Mesoblast Limited (NASDAQ:MESO) will report earnings of $-0.22 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.
Most recently Mesoblast Limited (NASDAQ:MESO) posted quarterly earnings of $-0.32 which compared to the sell-side estimates of -0.23. The stock’s 12-month trailing earnings per share stands at $-0.96. Shares have moved $18.31 over the past month and more recently, $16.26 over the past week heading into the earnings announcement. There are 1 analyst projections that were taken into consideration from respected brokerage firms.
Mesoblast Limited (NASDAQ:MESO) closed the last session at $6.7084 and sees an average of 49291.5 shares trade hands in each session. The 52-week low of the stock stands at $4.06 while the current level stands at 31.99% of the 52-week High-Low range. Looking further out we can see that the stock has moved -13.77% over the past 12 weeks and 25.39% year to date.
4 analysts rate Mesoblast Limited a Buy or Strong Buy, which is 66.67% of all the analyst ratings.
This article is informational purposes only and should not be considered a recommendation to buy or sell the stock.